

Special Issue

Biomedical Imaging and Cancers

Message from the Guest Editors

The discipline of radiology has been benefiting patients for over 100 years. A myriad of techniques are now available to image the human body both in terms of structure and function. The use of imaging in oncology has radically changed the patient treatment pathway, with the advent of radiomics and an increase in computing power; the use of artificial intelligence (AI) in biomedical imaging and cancers is now a real possibility. This Special Issue will encapsulate the uses of the latest imaging technologies for the purposes of diagnosis, staging, and treatment response in cancer. “Biomedical Imaging and Cancers” aims to cover new hybrid technology for acquisition and novel post-processing of imaging data to enhance and highlight biomarkers for detection of cancer, and the prediction and monitoring of responses to treatment. We are soliciting papers focusing on, but not limited to, new acquisition technology in imaging, novel methods of post processing, and machine learning and deep learning applied to imaging in cancer, biomarkers, and clinical trials.

Guest Editors

Prof. Dr. Norman R. Williams


Surgical & Interventional Trials Unit (SITU), Division of Surgery & Interventional Science, University College London, 3rd Floor, Charles Bell House, 43-45 Foley St, London W1W 7JN, UK

Dr. Anna Barnes

Institute of Nuclear Medicine, University College London Hospitals NHS-Foundation Trust, 235 Euston Rd, London NW1 2BU, UK

Deadline for manuscript submissions

closed (15 September 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/43853

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).